The diabetes medication exenatide did not slow motor symptom progression in treated Parkinson’s patients relative to those given a placebo, failing at the main goal of a Phase 3 study. Exenatide — sold in the U.S. under brand names including Byetta and Bydureon BCise, and used to help…

BlueRock Therapeutics said it is progressing its investigational cell therapy, bemdaneprocel, into a Phase 3 clinical trial set to begin in the first half of 2025. The trial, named exPDite-2, will assess the safety and efficacy of the treatment for moderate Parkinson’s disease. This decision comes after positive…

A flexible dose of experimental oral treatment tavapadon significantly lessened motor symptoms in adults with early-stage Parkinson’s disease, according to top-line results from a completed Phase 3 clinical trial. Developer Abbvie expects to present full results of the study, TEMPO-2 (NCT04223193), at a future medical meeting and…

A Phase 3 clinical trial evaluating investigational oral therapy solengepras as a treatment for Parkinson’s disease has dosed its first patient. The ARISE trial (NCT06553027) is evaluating the efficacy of solengepras as a potential add-on therapy to levodopa and other Parkinson’s medications. Patient recruitment is ongoing…

Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinson’s disease, and improved cognition in those with mild dementia. That’s according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio,…

Topline efficacy data from a Phase 3 clinical trial evaluating the oral therapy buntanetap for early-stage Parkinson’s disease is now expected in June, Annovis Bio, the therapy’s developer, has disclosed. While Annovis originally planned to share its early findings at the beginning of this year, the company faced…

Annovis Bio has announced the last patient completed the final visit in its Phase 3 clinical trial testing buntanetap for people with early-stage Parkinson’s disease. Since the study was initiated in August 2022, more than 616 patients were screened, 523 enrolled, and 471 completed the study across…

Following a positive safety review, Annovis Bio‘s Phase 3 clinical trial testing oral buntanetap for the treatment of early-stage Parkinson’s disease can move forward as originally designed, the company announced. That positive review came from the Data and Safety Monitoring Board (DSMB), an independent group of experts, which…

New trial data suggest that the combination therapy P2B001 for early Parkinson’s disease may offer effective symptom control with significantly fewer side effects — notably, less daytime sleepiness — than available treatments. The therapy, being developed by the Israeli-based Pharma Two B, could potentially be a first-line,…

The first patient has been dosed in a clinical trial testing Annovis Bio’s buntanetap as an oral therapy for early-stage Parkinson’s disease, the company announced. The Phase 3 clinical trial (NCT05357989) got started shortly after the U.S. Food and Drug Administration (FDA) gave the company the…